Recent developments: Breast cancer
- 16 February 2002
- Vol. 324 (7334), 410-414
- https://doi.org/10.1136/bmj.324.7334.410
Abstract
MethodsWe selected topics on the basis of their current or likely future impact on practice, with an emphasis on areas in which significant changes in our knowledge base have occurred in the past three to five years. We did English language Medline searches, giving priority to prospective randomised trials or large prospective multi-institutional studies when available. We also reviewed abstracts from meetings on breast cancer in the past three years.Keywords
This publication has 27 references indexed in Scilit:
- Multicenter Trial of Sentinel Node Biopsy for Breast Cancer Using Both Technetium Sulfur Colloid and Isosulfan Blue DyeAnnals of Surgery, 2001
- Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control studyThe Lancet, 2000
- Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized TrialJournal of Clinical Oncology, 2000
- Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability StudyJournal of Clinical Oncology, 2000
- ICI 182,780 (Faslodex?)Cancer, 2000
- Long-term Satisfaction and Psychological and Social Function Following Bilateral Prophylactic MastectomyJAMA, 2000
- Prospective Observational Study of Sentinel Lymphadenectomy Without Further Axillary Dissection in Patients With Sentinel Node–Negative Breast CancerJournal of Clinical Oncology, 2000
- The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.2000
- Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.2000
- Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation CarriersJNCI Journal of the National Cancer Institute, 1999